肺腺癌对Alectinib有应答的病例,其中含有罕见的EML4-ALK变异,EML4的外显子6与ALK的外显子18融合。

IF 16.4
Lirong Liu, Fangfang Hou, Yufeng Liu, Wenzhu Li, Haibo Zhang
{"title":"肺腺癌对Alectinib有应答的病例,其中含有罕见的EML4-ALK变异,EML4的外显子6与ALK的外显子18融合。","authors":"Lirong Liu,&nbsp;Fangfang Hou,&nbsp;Yufeng Liu,&nbsp;Wenzhu Li,&nbsp;Haibo Zhang","doi":"10.6004/jnccn.2021.7077","DOIUrl":null,"url":null,"abstract":"<p><p>More than 20 types of ALK fusion variant subtypes have been identified, including different fusion partner genes or EML4-ALK fusions with different breakpoints. However, different ALK fusions show different sensitivities to ALK-tyrosine kinase inhibitors (ALK-TKIs) and the emergence of rare fusions brings great challenges to the target therapy in clinic. We report a rare EML4-ALK (E6;A18) fusion in a patient with lung adenocarcinoma that responded well to alectinib. This is the second case of this rare variant reported but the first report of response to an ALK-TKI. This evidence is the first to show that alectinib may be effective for this rare fusion type of non-small cell lung cancer, and these findings have important implications for drug selection in patients with this subtype. Further studies are needed to understand the function of this variant.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":"2-6"},"PeriodicalIF":16.4000,"publicationDate":"2021-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.\",\"authors\":\"Lirong Liu,&nbsp;Fangfang Hou,&nbsp;Yufeng Liu,&nbsp;Wenzhu Li,&nbsp;Haibo Zhang\",\"doi\":\"10.6004/jnccn.2021.7077\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>More than 20 types of ALK fusion variant subtypes have been identified, including different fusion partner genes or EML4-ALK fusions with different breakpoints. However, different ALK fusions show different sensitivities to ALK-tyrosine kinase inhibitors (ALK-TKIs) and the emergence of rare fusions brings great challenges to the target therapy in clinic. We report a rare EML4-ALK (E6;A18) fusion in a patient with lung adenocarcinoma that responded well to alectinib. This is the second case of this rare variant reported but the first report of response to an ALK-TKI. This evidence is the first to show that alectinib may be effective for this rare fusion type of non-small cell lung cancer, and these findings have important implications for drug selection in patients with this subtype. Further studies are needed to understand the function of this variant.</p>\",\"PeriodicalId\":520697,\"journal\":{\"name\":\"Journal of the National Comprehensive Cancer Network : JNCCN\",\"volume\":\" \",\"pages\":\"2-6\"},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2021-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Comprehensive Cancer Network : JNCCN\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.6004/jnccn.2021.7077\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Comprehensive Cancer Network : JNCCN","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6004/jnccn.2021.7077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

目前已鉴定出20多种ALK融合变异亚型,包括不同的融合伙伴基因或具有不同断点的EML4-ALK融合。然而,不同的ALK融合体对ALK-酪氨酸激酶抑制剂(ALK- tkis)的敏感性不同,罕见融合体的出现给临床的靶向治疗带来了很大的挑战。我们报道一例罕见的EML4-ALK (E6;A18)融合在一例肺腺癌患者中,该患者对阿勒替尼反应良好。这是报告的第二例这种罕见变异,但对ALK-TKI反应的首次报告。这一证据首次表明alectinib可能对这种罕见的融合型非小细胞肺癌有效,这些发现对该亚型患者的药物选择具有重要意义。需要进一步的研究来了解这种变异的功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.

More than 20 types of ALK fusion variant subtypes have been identified, including different fusion partner genes or EML4-ALK fusions with different breakpoints. However, different ALK fusions show different sensitivities to ALK-tyrosine kinase inhibitors (ALK-TKIs) and the emergence of rare fusions brings great challenges to the target therapy in clinic. We report a rare EML4-ALK (E6;A18) fusion in a patient with lung adenocarcinoma that responded well to alectinib. This is the second case of this rare variant reported but the first report of response to an ALK-TKI. This evidence is the first to show that alectinib may be effective for this rare fusion type of non-small cell lung cancer, and these findings have important implications for drug selection in patients with this subtype. Further studies are needed to understand the function of this variant.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信